- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04691570
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)
January 17, 2024 updated by: Annexon, Inc.
A Phase 2, Open-Label, Repeat Dose Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Intravenous ANX005 in Subjects With Warm Autoimmune Hemolytic Anemia (wAIHA)
This study will evaluate the safety and tolerability of ANX005 in participants with Warm Autoimmune Hemolytic Anemia (wAIHA).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
After being informed of study details and potential risks, all participants who provide written informed consent will undergo an up to 6-week screening period to determine eligibility.
Participants who meet the eligibility criteria will receive two once-weekly intravenous (IV) infusions of ANX005.
Participants will return to the clinic weekly through Week 10 for study assessments.
The total duration of individual participation in this study will be up to 16 weeks.
Study Type
Interventional
Enrollment (Actual)
6
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Investigational Site 01
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male or non-pregnant, non-lactating female ≥18 years of age (no maximum age).
- Diagnosis of wAIHA at least 3 months prior to screening with a direct antiglobulin test (DAT) ≥1 positive for immunoglobulin G (IgG)±C3, or a diagnosis of mixed autoimmune hemolytic anemia (AIHA) that is DAT positive for both IgG and C3, with a presence of a cold antibody with a thermal amplitude ≥30ºCelcius.
- Hemoglobin (Hgb) level ≤10.0 grams/deciliter (pre-transfusion).
- Evidence of classical complement pathway activation.
- Evidence of active hemolysis.
- Stable use of glucocorticoids and immunosuppressants are permitted.
- Vaccinations against encapsulated bacterial organisms within 5 years prior to screening or participant must be willing to receive prophylaxis against infections with encapsulated bacteria via vaccination and/or the use of prophylactic antibiotics in accordance with local standards of practice and/or guidelines.
Exclusion Criteria:
- Elevated aspartate aminotransferase or alanine aminotransferase levels >2.5 times the upper limit of normal.
- Platelet count <30 X 10^9/liter.
- History of cold agglutinin disease.
- History of solid organ, bone marrow, or stem cell transplantation.
- History of splenectomy within the 3 months prior to screening.
- Received rituximab or other anti-CD20 monoclonal antibody <3 months prior to screening.
- Intravenous immunoglobulin (IVIg) treatment within 3 months prior to screening or plasmapheresis or immunoadsorption treatment within 60 days prior to screening.
- Clinically significant, recent, or ongoing illness or medical condition, including coexistent autoimmune disorder, malignancy, HIV, hepatitis B virus, and hepatitis C virus.
- History of meningitis or septicemia within the past 2 years.
- Treatment with an investigational therapeutic agent within 30 days prior to screening.
- Hypersensitivity to any drug product or excipients used in this study or to previous IV medication administration.
- Body weight less than 50 kilograms (kg) or greater than 100 kg
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ANX005
Participants will receive two once-weekly doses of ANX005 at specific time points
|
ANX005 is provided as a solution for IV infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety: Treatment-emergent adverse events (TEAEs)
Time Frame: Up to Week 16
|
Number of participants with TEAEs, defined as any adverse event with an onset on or after the day of infusion through 16 weeks after the infusion
|
Up to Week 16
|
Change in disease activity biomarkers
Time Frame: Baseline to Day 71
|
Change in hemoglobin, lactate dehydrogenase, bilirubin, reticulocyte count and haptoglobin from baseline
|
Baseline to Day 71
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma concentrations
Time Frame: Up to Day 71
|
Plasma concentrations of ANX005 over time
|
Up to Day 71
|
Change in complement system biomarkers
Time Frame: Baseline to Day 71
|
Change in CH50 and C1q from baseline
|
Baseline to Day 71
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Study Director, Annexon, Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 10, 2021
Primary Completion (Actual)
January 17, 2023
Study Completion (Actual)
January 17, 2023
Study Registration Dates
First Submitted
December 28, 2020
First Submitted That Met QC Criteria
December 30, 2020
First Posted (Actual)
December 31, 2020
Study Record Updates
Last Update Posted (Actual)
January 19, 2024
Last Update Submitted That Met QC Criteria
January 17, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ANX005-wAIHA-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Warm Autoimmune Hemolytic Anemia (wAIHA)
-
SanofiActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)United States, Austria, China, Denmark, Germany, Hungary, Italy, Spain, United Kingdom
-
SanofiTerminatedWarm Autoimmune Hemolytic Anemia (wAIHA)United Kingdom, Belgium, Netherlands, France, United States, Germany, Hungary, Italy
-
Novartis PharmaceuticalsRecruitingWarm Autoimmune Hemolytic Anemia (wAIHA)China, Japan, Spain, Singapore, France, Germany, Taiwan, United States, Italy, India, Malaysia, Argentina, Hungary, Israel, Australia, Thailand, United Kingdom, Romania
-
Incyte CorporationActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)Spain, United States, Austria, Belgium, Canada, France, Germany, Israel, Italy, Japan, Netherlands, Poland, United Kingdom
-
Eugene NikitinUnknownAIHA - Warm Autoimmune Hemolytic AnemiaRussian Federation
-
Bioverativ, a Sanofi companyAssign Data Management and Biostatistics GmbH; Quest Diagnostics-Nichols Insitute and other collaboratorsCompletedEnd-stage Renal Disease (ESRD) | Cold Agglutinin Disease (CAD) | Bullous Pemphigoid (BP) | Warm Autoimmune Hemolytic Anemia (WAIHA)Austria
-
Peking Union Medical College HospitalRecruiting
-
Alexion PharmaceuticalsWithdrawnWarm Autoimmune Hemolytic AnemiaUnited States
-
Alexion PharmaceuticalsTerminatedWarm Autoimmune Hemolytic AnemiaUnited States, Jordan
-
Chen MiaoNot yet recruiting
Clinical Trials on ANX005
-
Annexon, Inc.RecruitingAmyotrophic Lateral SclerosisUnited States, Canada
-
Annexon, Inc.CompletedHuntington DiseaseUnited States
-
Annexon, Inc.TerminatedSafety and Tolerability in Healthy VolunteersAustralia
-
Annexon, Inc.RecruitingGuillain-Barre SyndromeBangladesh, Philippines
-
Annexon, Inc.International Centre for Diarrhoeal Disease Research, Bangladesh; ResearchPoint...CompletedGuillain-Barré SyndromeDenmark, Bangladesh